Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial

Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial

Summary: Background: Safe and effective vaccines are urgently needed to end the COVID-19 pandemic caused by SARS-CoV-2 infection. We aimed to assess the preliminary safety, tolerability, and immunogenicity of an mRNA vaccine ARCoV, which encodes the SARS-CoV-2 spike protein receptor-binding domain...

Full description

Bibliographic Details
Main Authors: Gui-Ling Chen, MD, Xiao-Feng Li, ProfPhD, Xia-Hong Dai, PhD, Nan Li, BD, Meng-Li Cheng, MSc, Zhen Huang, MSc, Jian Shen, MD, Yu-Hua Ge, BD, Zhen-Wei Shen, PhD, Yong-Qiang Deng, PhD, Shu-Yuan Yang, MSc, Hui Zhao, PhD, Na-Na Zhang, MSc, Yi-Fei Zhang, BSc, Ling Wei, MSc, Kai-Qi Wu, MD, Meng-Fei Zhu, ProfPhD, Cong-Gao Peng, MD, Qi Jiang, BD, Shou-Chun Cao, ProfPhD, Yu-Hua Li, ProfPhD, Dan-Hua Zhao, PhD, Xiao-Hong Wu, PhD, Ling Ni, PhD, Hua-Hao Shen, PhD, Chen Dong, ProfPhD, Bo Ying, PhD, Guo-Ping Sheng, PhD, Cheng-Feng Qin, ProfPhD, Hai-Nv Gao, ProfPhD, Lan-Juan Li, ProfPhD
Format: Article
Language:English
Published: Elsevier 2022-03-01
Series:The Lancet Microbe
Online Access:http://www.sciencedirect.com/science/article/pii/S2666524721002809

Internet

http://www.sciencedirect.com/science/article/pii/S2666524721002809

Similar Items